BRAF and thyroid cancer: Furthermore, the BRAF V600E oncogene induces transforming growth factor-beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer [8], and targeted expression of BRAF V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation [9].